Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.18
-0.01 (-0.19%)
Sep 15, 2025, 11:07 AM EDT - Market open
Foghorn Therapeutics Revenue
Foghorn Therapeutics had revenue of $7.56M in the quarter ending June 30, 2025, with 9.71% growth. This brings the company's revenue in the last twelve months to $24.17M, down -31.30% year-over-year. In the year 2024, Foghorn Therapeutics had annual revenue of $22.60M, down -33.83%.
Revenue (ttm)
$24.17M
Revenue Growth
-31.30%
P/S Ratio
13.49
Revenue / Employee
$215,830
Employees
112
Market Cap
292.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.60M | -11.55M | -33.83% |
Dec 31, 2023 | 34.16M | 14.93M | 77.63% |
Dec 31, 2022 | 19.23M | 17.91M | 1,357.77% |
Dec 31, 2021 | 1.32M | 889.00K | 206.74% |
Dec 31, 2020 | 430.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FHTX News
- 18 days ago - IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies - PRNewsWire
- 19 days ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - GlobeNewsWire